Stock Notes

Morepen Laboratories

Every Finvezto stock note on Morepen Laboratories, dated and newest first. Coverage spans pharmaceuticals.

1 note and counting
07 Sep 2026
Morepen Laboratories finished the first phase of its capacity expansion early, lifting reactor capacity from 535 KL to 614 KL.
The capacity supports its 825 crore rupee CDMO mandate and the existing API business. The roadmap runs to 800 KL by the second quarter of FY28 and 1,200 KL by FY30.
Finvezto Membership

Get the research behind the notes

Stock notes are the free daily layer. The membership carries the full Flexi-Wealth system: an ETF core portfolio with monthly rebalancing signals, fifteen quality-momentum stocks with exact weightages every month, options income and hedging recommendations, and the institutional data toolkit. One flat membership covers everything.

Become a Member Read free sample research →

Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630. Stock notes are market commentary for general information and education. They are not investment advice, not a recommendation to buy or sell, and do not account for any individual's financial situation. Investment in securities is subject to market risks. Please read all related documents carefully before investing. Past performance is not a guarantee of future results.